• Tiziana Life Sciences published its INFORM-MS presentation, reporting that intranasal foralumab met both primary endpoints in Phase 2 non-active secondary progressive MS.
• The 50-microgram dose significantly reduced neuroinflammation versus placebo at 12 weeks (p=0.0168); the exploratory 100-microgram arm showed no significant PET change.
• Fatigue scores improved 6.17 points with 50 micrograms and 7.18 points with 100 micrograms; comparisons were within treatment groups, not versus placebo.
• Neither dose caused study-drug-related serious adverse events; all 48 participants completed treatment without discontinuations due to adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.